Vertex tightens CF focus as promising flu candidate out-licensed to Janssen
This article was originally published in Scrip
Executive Summary
J&J subsidiary Janssen has agreed to pay $30m upfront to Vertex Pharmaceuticals for global development and commercialization rights to a novel influenza candidate with a mechanism of action distinct from neuraminidase inhibitors, the current standard of care for the treatment of flu.